Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NasdaqGS:GLXY
NasdaqGS:GLXYCapital Markets

Galaxy Digital (GLXY) Is Up 6.8% After Expanding ATM Capacity And Launching Onchain Sweep Fund

In early May 2026, Galaxy Digital Inc. filed a US$500 million at-the-market follow-on offering and a roughly US$7.77 billion shelf registration covering up to 265,061,636 Class A shares plus a broad mix of other securities. Just days earlier, State Street Investment Management and Galaxy Asset Management launched the State Street Galaxy Onchain Liquidity Sweep Fund on Solana, underscoring Galaxy’s role in bringing tokenized cash management and stablecoin-based fund access to institutional...
NasdaqGS:PHVS
NasdaqGS:PHVSPharmaceuticals

The Bull Case For Pharvaris (PHVS) Could Change Following Dilutive US$115 Million Equity Raise - Learn Why

Pharvaris N.V. recently completed a follow-on equity offering of 3,874,664 ordinary shares at US$29.68 per share, raising about US$115.00 million in gross proceeds, after earlier announcing the transaction and granting underwriters a 30-day option to buy up to 581,199 additional shares. The deal, coming shortly after the Chief Medical Officer’s cashless exercise and sale of stock options, highlights both the company’s drive to bolster its cash position and the active role of insiders in...
NasdaqGS:OLMA
NasdaqGS:OLMABiotechs

How Investors May Respond To Olema Pharmaceuticals (OLMA) Adding Biopharma Deal-Maker Prakash Raman To Board

In April 2026, Olema Pharmaceuticals appointed Prakash Raman, Ph.D., a veteran biopharma executive and current CEO of InduPro Therapeutics, to its Board of Directors. Raman’s extensive background in oncology collaborations and deal-making at Novartis, Flagship Pioneering, and multiple biotech leadership roles adds significant business development depth to Olema’s governance. Next, we will examine how Raman’s oncology-focused business development experience could influence Olema...
NasdaqGS:PAYX
NasdaqGS:PAYXProfessional Services

Did Paychex’s (PAYX) 10% Dividend Hike Amid Firm Job Trends Just Reframe Its Stability Story?

In early May 2026, Paychex, Inc. raised its regular quarterly cash dividend to US$1.19 per share, a US$0.11 (10%) increase from the prior US$1.08, payable on May 29, 2026 to shareholders of record on May 13, 2026. Around the same time, the company’s Small Business Employment Watch showed a second straight month of improving U.S. small-business job growth, highlighting resilience in Paychex’s core client base. Next, we’ll examine how this 10% dividend increase could influence Paychex’s...
NasdaqGS:CDW
NasdaqGS:CDWElectronic

CDW’s AI Shift Targets US$200m Savings And Potential Valuation Upside

CDW (NasdaqGS:CDW) has launched an AI first program called "Geared for Growth" across its operations and go to market model. The initiative seeks up to US$200 million in annual run rate savings targeted for 2027 to 2028. The program focuses on embedding AI into internal processes and customer facing activities to improve productivity and efficiency. CDW is a technology solutions provider, so an AI first shift sits directly in the flow of what customers are asking for across infrastructure,...
NYSE:PRLB
NYSE:PRLBMachinery

Assessing Proto Labs (PRLB) Valuation After Strong Recent Share Price Momentum

Why Proto Labs Stock Is Drawing Attention Now Proto Labs (PRLB) is back on many investors’ radar after a recent share price move, with the stock showing a return of about 18% over the past month and 33% year to date. See our latest analysis for Proto Labs. The recent 1 month share price return of 18.5% and year to date share price return of 32.8% come on top of a 1 year total shareholder return of 69.6%, suggesting momentum has been building rather than fading. If Proto Labs has caught your...
NasdaqGS:PAA
NasdaqGS:PAAOil and Gas

Is Plains All American Pipeline (PAA) Still Attractive After A 41.7% One Year Rally?

Wondering if Plains All American Pipeline at around US$22 is still offering value, or if most of the opportunity is already priced in. The stock last closed at US$22.09, with a 4% decline over the past week, a 0.7% decline over the past month, a 21.3% gain year to date and a 41.7% return over the past year. Recent coverage around Plains All American Pipeline has focused on its position within the energy infrastructure space and how investors are weighing income potential against exposure to...
NYSE:CXW
NYSE:CXWCommercial Services

Assessing CoreCivic (CXW) Valuation After Recent Share Price Momentum

CoreCivic stock: why recent returns are catching investor attention CoreCivic (CXW) has been drawing fresh interest after a stretch of mixed returns, with gains over the past month and past 3 months alongside a slightly negative 1 year total return. For readers tracking performance, the stock shows a 3.1% 1 day return, 6.6% over the past week, 9.2% over the past month and 16.6% over the past 3 months, while the 1 year total return sits at about a 0.9% decline. See our latest analysis for...
NYSE:CARR
NYSE:CARRBuilding

Will Surging Data Center Orders and Growing Services Shift Carrier Global's (CARR) Core Narrative?

In the past quarter, Carrier Global Corporation reported first quarter 2026 revenue of US$5,341 million versus US$5,218 million a year earlier, while net income fell to US$238 million from US$412 million, and the company reaffirmed its full‑year 2026 sales outlook of about US$22.00 billion. Management highlighted that global data center orders increased by a very large amount year over year, with backlog already covering the US$1.50 billion data center sales target for 2026 and aftermarket...
NYSE:PAYC
NYSE:PAYCProfessional Services

Is It Time To Revisit Paycom Software (PAYC) After A Steep One Year Share Price Slide?

Wondering if Paycom Software at around US$138 a share is a bargain or a value trap? This article walks through what the current price actually implies. The stock has shown a 9.2% return over the last 7 days and 11.4% over the last 30 days. Yet year to date it sits at a 9.2% loss and a 44.0% loss over the past year, which naturally raises questions about risk and potential recovery. Recent coverage has focused on how Paycom Software fits into the broader professional services and software...
NYSE:FDS
NYSE:FDSCapital Markets

How Investors Are Reacting To FactSet Research Systems (FDS) J.P. Morgan Collaboration And Dividend Increase

In late April 2026, FactSet Research Systems Inc. and J.P. Morgan announced the launch of a Whole Portfolio Distribution solution, giving institutional investors a unified, automated view of portfolios across asset classes and data sources through FactSet, powered by Fusion by J.P. Morgan and already supporting US$62.50 billion in Assets under Analysis. In early May 2026, FactSet Research Systems Inc. also approved a higher quarterly dividend of US$1.16 per share payable on June 18, 2026,...
TASE:ELTR
TASE:ELTRConstruction

Electra (TASE:ELTR) Valuation Check After Volatile Recent Share Price Performance

What Electra’s Recent Share Performance Signals for Investors With no single headline event driving Electra (TASE:ELTR) today, investors are focusing on how the stock’s recent performance lines up with its fundamentals, including revenue of ₪13,953 and net income of ₪168. See our latest analysis for Electra. Recent trading has been volatile, with a 12.1% 7 day share price return and an 18.5% 30 day share price return. Year to date share price performance is slightly weaker and the 1 year...
NYSE:EFX
NYSE:EFXProfessional Services

Assessing Equifax (EFX) Valuation After Recent Share Price Momentum Without A Clear News Catalyst

Equifax (EFX) stock has been moving without a clear single news catalyst, leaving investors focused on its recent share performance, current valuation signals, and the latest snapshot of its business fundamentals. See our latest analysis for Equifax. At a share price of $175.62, Equifax has seen a 1-day share price return of 1.40%. Its year to date share price return of 17.95% and 1-year total shareholder return of 34.65% indicate changing momentum following earlier weakness. If you are...
NYSE:CTS
NYSE:CTSElectronic

A Look At CTS (CTS) Valuation After Strong Q1 2026 Beat And Higher Sales Guidance

CTS (CTS) has caught investor attention after first quarter 2026 earnings exceeded analyst expectations and management raised full year sales guidance, prompting closer scrutiny of what is driving the stock at recent highs. See our latest analysis for CTS. The recent 1 month share price return of 21.01% and year to date share price return of 36.49% suggest momentum has been building, supported by first quarter earnings, raised 2026 sales guidance and continued buybacks. The 1 year total...
NYSE:VICI
NYSE:VICISpecialized REITs

A Look At VICI Properties (VICI) Valuation After Raised AFFO Guidance And First Quarter 2026 Results

VICI Properties (VICI) just posted first quarter 2026 results, reporting revenue of US$1.02b and net income of US$872.39m, and raised full year AFFO guidance on the back of acquisitions and lending activity. See our latest analysis for VICI Properties. At a share price of US$28.79, VICI’s 30 day share price return of 3.45% contrasts with a 1 year total shareholder return of 3.24% decline. This suggests recent momentum is improving after a softer year, as investors weigh the raised AFFO...
NYSE:PINS
NYSE:PINSInteractive Media and Services

Pinterest Lawsuits Put Spotlight On Advertising Disclosures And Valuation Gap

Multiple securities fraud class action lawsuits have been filed against Pinterest (NYSE:PINS), targeting the company and certain executives. The suits claim Pinterest misled investors about advertising revenue pressures, the effects of U.S. tariffs, and upcoming restructuring plans. These cases are at an early stage, with a lead plaintiff deadline still pending. Pinterest runs a visual discovery platform that connects users with products and ideas, and its business model relies heavily on...
NasdaqGS:SDGR
NasdaqGS:SDGRHealthcare Services

A Look At Schrödinger (SDGR) Valuation After Earnings Miss And Bunsen AI Co Scientist Launch Plans

Schrödinger (SDGR) is back in focus after first quarter 2026 results combined a reported earnings miss with 12% growth in Annual Contract Value, along with fresh attention on its upcoming Bunsen AI co-scientist launch. See our latest analysis for Schrödinger. Recent trading reflects this renewed interest, with a 1 month share price return of 16.59% and 7 day share price return of 11.04%. However, the year to date share price return of negative 26.14% and 1 year total shareholder return of...
NYSE:ACHR
NYSE:ACHRAerospace & Defense

Archer Aviation (ACHR) Valuation Check As Sentiment Splits Between Fair Value And DCF Upside

With no clear single event driving headlines, Archer Aviation (ACHR) has still drawn attention as the stock shifted from a recent monthly gain to a decline over the past three months and the past year. See our latest analysis for Archer Aviation. Archer Aviation's recent share price return shows short term momentum, with a 7 day gain of 9.41% and a 30 day gain of 17.60%. However, this follows a 90 day share price decline of 13.97% and a 1 year total shareholder return of 28.31% in the red...
NasdaqGM:ACMR
NasdaqGM:ACMRSemiconductor

ACM Research (ACMR) Margin Compression To 9.5% Tests Bullish Growth Narrative

ACM Research (ACMR) opened 2026 with Q1 revenue of US$231.3 million and basic EPS of US$0.26, alongside trailing twelve month revenue of US$960.2 million and EPS of US$1.40 that frame the latest quarterly print. Over the past six quarters, the company has seen quarterly revenue range from US$172.3 million to US$269.2 million and basic EPS move between US$0.12 and US$0.56, giving investors a clear view of how top line and per share earnings have tracked into the current TTM profile. With...
NasdaqGS:CGON
NasdaqGS:CGONBiotechs

CG Oncology (CGON) Deep LTM Losses Test Bullish Late Stage Pipeline Narratives

CG Oncology (CGON) has just closed out FY 2025 with Q4 revenue of US$2.3 million and a basic EPS loss of US$0.52, alongside a net income loss of US$41.3 million, as the company continues to invest heavily in its pipeline. Over the last twelve months, revenue has summed to US$4.0 million and basic EPS has come in at a loss of US$2.08. This gives investors a clear view of a business that is still in a development phase and running with intentionally thin margins while it pushes its late stage...
NYSE:NVST
NYSE:NVSTMedical Equipment

Is It Time To Reassess Envista Holdings (NVST) After Its Recent Share Price Pullback

If you are wondering whether Envista Holdings at US$24.29 offers good value or is already fully priced, the recent share performance gives you a useful starting point. The stock has pulled back 6.4% over the last 7 days and 4.0% over the last 30 days. It sits 12.0% higher year to date and 36.7% above where it was a year ago, while the 3 year and 5 year returns of 26.7% and 44.7% highlight a tougher longer term journey. Recent coverage has focused on Envista Holdings as a dental equipment and...
NYSE:AIZ
NYSE:AIZInsurance

A Look At Assurant (AIZ) Valuation After Its Q1 2026 Earnings Beat And Guidance Raise

Assurant (AIZ) just paired a strong Q1 2026 earnings beat with higher full year guidance and continued share repurchases, putting the spotlight on how its Global Lifestyle driven momentum might affect the stock. See our latest analysis for Assurant. Despite the strong Q1 surprise and ongoing buybacks, Assurant’s recent trading has been mixed, with a 6.86% 1 month share price return but a 1.65% year to date share price decline. In contrast, the 1 year total shareholder return of 21.86% and 3...
NasdaqGM:VERA
NasdaqGM:VERABiotechs

A Look At Vera Therapeutics (VERA) Valuation After FDA Priority Review For Atacicept In IgA Nephropathy

Earnings picture during a key regulatory phase Vera Therapeutics (VERA) reported a first quarter net loss of US$121.03 million, compared with US$51.69 million a year earlier, as it pushes atacicept toward potential approval for IgA nephropathy. Basic and diluted loss per share from continuing operations came in at US$1.69, versus US$0.81 in the prior year period. This provides a snapshot of how much capital the company is currently investing ahead of the July 7, 2026 FDA decision. See our...
ASX:ALL
ASX:ALLHospitality

Digital Gaming Push and Recurring Revenue Shift Could Be A Game Changer For Aristocrat Leisure (ASX:ALL)

In recent days, Aristocrat Leisure’s expansion in digital gaming and its growing international footprint have kept the company in the spotlight, particularly as its recurring revenue base strengthens. An interesting angle is how the digital division’s recurring revenue and US demand are helping Aristocrat broaden its role in Australia’s entertainment technology sector. We’ll now examine how this digital expansion emphasis shapes Aristocrat Leisure’s broader investment narrative and the way...